Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients

(2020) Valérie Dutoit et al.   Frontiers in Oncology

Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients

(2020) Carrie Anne Minnaar et al.   Frontiers in Oncology

Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials

(2020) Li Lv et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

(2020) Stefaan W. Van Gool et al.   Cancers

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

(2019) Paul Daniel et al.   Frontiers in Oncology

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

(2019) Sabrina Heynckes et al.   BMC CANCER

Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

(2019) MARKOS ANTONOPOULOS et al.   ANTICANCER RESEARCH

Oncogene-induced senescence and tumour control in complex biological systems

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts

(2018) Tamas Vancsik et al.   Journal of Cancer

Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study

(2018) Chan Woo Wee et al.   RADIOTHERAPY AND ONCOLOGY

Dendritic cell vaccines for high-grade gliomas

(2018) Matthew Eagles et al.   Therapeutics and Clinical Risk Management

Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review

(2018) Bogdan Ionel Vatu et al.   JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

(2016) Abhishek D. Garg et al.   Science Translational Medicine

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010

(2015) Chaturia Rouse et al.   NEURO-ONCOLOGY

Brain Tumor Immunotherapy: What have We Learned so Far?

(2015) Stefaan Willy Van Gool   Frontiers in Oncology

Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review

(2014) Xuan Wang et al.   CANCER INVESTIGATION

Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis

(2014) Jun-Xia Cao et al.   PLoS One

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

(2013) Laura Ridolfi et al.   Journal of Translational Medicine

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY